Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

32.73USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$32.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,115,295
52-wk High
$58.15
52-wk Low
$31.91

Latest Key Developments (Source: Significant Developments)

OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico
Monday, 20 Mar 2017 10:07am EDT 

OncBioMune Pharmaceuticals Inc : OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico . Term sheet sets forth guidelines for co to acquire sanitary registration, intellectual property rights of Norepinefrine .Norepinefrine is currently owned by Teva.  Full Article

Teva says FDA granted priority review for SD-809 for treatment of tardive dyskinesia
Tuesday, 28 Feb 2017 08:00am EST 

Teva Pharmaceutical Industries Ltd : Teva Pharmaceutical Industries Ltd - FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 30, 2017. .Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia.  Full Article

Teva sees 2017 adjusted profit $4.90 to $5.30/shr
Monday, 13 Feb 2017 06:42am EST 

Teva Pharmaceutical Industries Ltd : Teva reports full year and fourth quarter 2016 financial results . Sees fy 2017 non-gaap earnings per share $4.90 to $5.30 . Sees fy 2017 revenue $23.8 billion to $24.5 billion . Q4 revenue rose 33 percent to $6.5 billion . Teva pharmaceutical industries ltd - reaffirms its 2017 full year non-gaap guidance . Teva pharmaceutical industries ltd - teva reaffirms its 2017 full year non-gaap guidance . Teva pharmaceutical industries ltd - qtrly non-gaap eps $1.38 . Teva pharmaceutical industries ltd- generic medicines revenues in q4 of 2016 were $3.7 billion, an increase of 44% compared to q4 of 2015 . Teva pharmaceutical industries ltd - qtrly gaap loss per share $1.10 . Teva pharmaceutical industries ltd says specialty medicines revenues in q4 of 2016 were $2.2 billion, up 4% compared to q4 of 2015 .Teva pharmaceutical industries ltd - qtrly global revenues of copaxone in u.s. And globally, were $1.0 billion, an increase of 6% compared to q4 of 2015.  Full Article

Teva appoints Dr. Yitzhak Peterburg as interim CEO
Monday, 6 Feb 2017 04:53pm EST 

Teva Pharmaceutical Industries Ltd : Teva appoints Dr. Yitzhak Peterburg as interim chief executive officer, succeeding Erez Vigodman . Teva Pharmaceutical Industries Ltd - Sol J. Barer named chairman of board . Teva Pharmaceutical Industries Ltd - board of directors is undertaking a search to identify a permanent chief executive officer . Teva Pharmaceutical Industries Ltd- Yitzhak Peterburg has stepped down from his role as chairman in order to serve as interim chief executive officer .Teva Pharmaceutical Industries Ltd says Erez Vigodman is stepping down following a mutual agreement between board of Teva and Vigodman.  Full Article

Teva confirms generic Victoza patent challenge in the United States
Thursday, 2 Feb 2017 08:00am EST 

Teva Pharmaceutical Industries Ltd : Teva confirms generic Victoza patent challenge in the united states . Teva Pharmaceutical Industries Ltd - filed ANDA with FDA seeking approval to market generic version of Novo Nordisk's Victoza (liraglutide) injection .Teva Pharmaceutical Industries Ltd - should its ANDA be approved, Teva may be entitled to 180 days of generic market exclusivity.  Full Article

ISS Germany wins contract with Teva Pharmaceuticals
Wednesday, 1 Feb 2017 09:40am EST 

Iss A/S : ISS Germany wins contract with Teva Pharmaceuticals . ISS Germany's Pharma Services will serve as Teva GmbH's new facility services provider .Teva has signed a 5-year contract with ISS, effective Jan. 1.  Full Article

Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation
Tuesday, 31 Jan 2017 08:00am EST 

Momenta Pharmaceuticals Inc :Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation.  Full Article

U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta
Thursday, 12 Jan 2017 10:16am EST 

U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling : U.S. Court of appeals for the federal circuit upholds lower court finding that teva was liable for inducing infringement by doctors Further company coverage: [LLY.N].  Full Article

Teva reaches settlement with government on FCPA
Thursday, 22 Dec 2016 09:15am EST 

Teva Pharmaceutical Industries Ltd : Teva reaches settlement with government on FCPA . Teva Pharmaceutical - co, DoJ and sec have agreed to a resolution to resolve previously disclosed investigations into conduct relating to three countries . Resolution also includes previously reserved payments totaling $519 million . Conclusion of negotiations with united states government over violations of foreign corrupt practices act . Teva Pharmaceutical industries - resolution includes a deferred prosecution agreement, implementation of a temporary independent compliance monitor . Teva Pharmaceutical - to resolve previously disclosed investigations into conduct relating to 3 countries - Ukraine, Mexico and a guilty plea by unit in Russia .Teva Pharmaceutical industries- resolution involves conduct occurring in past, and none of the employees involved in improper payments are still employed.  Full Article

Teva, IBM to enable drug development and chronic disease management with Watson
Wednesday, 26 Oct 2016 07:00am EDT 

International Business Machines Corp: Teva Pharmaceuticals and IBM expand global partnership to enable drug development and chronic disease management with Watson . IBM - collaboration features first integration of weather company data with IBM Watson health cloud . IBM - projects will run on IBM Watson health cloud . IBM - expanded partnership features three-year research collaboration to develop cognitive technologies .IBM - companies announced that respiratory and central nervous system diseases will be first targets for chronic disease management initiative.  Full Article

More From Around the Web

Teva Pharm says media reports of up to 6,000 layoffs incorrect

JERUSALEM Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.